For the quarter ending 2026-03-31, ALKS had -$768,225K decrease in cash & cash equivalents over the period. -$169,833K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | - | 384,547 | - | - |
| Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | - | 46,209 | - | - |
| Alixorexton | - | 28,302 | - | - |
| Lybalvi | - | 5,096 | - | - |
| Other external r&d expenses | - | 18,549 | - | - |
| Total external r&d expenses | - | 51,947 | - | - |
| Employee-related | - | 33,088 | - | - |
| Occupancy | - | 3,305 | - | - |
| Depreciation | - | 1,259 | - | - |
| Other internal r&d expenses | - | 3,439 | - | - |
| Total internal r&d expenses | - | 41,091 | - | - |
| R&d expenses | - | 93,038 | - | - |
| Selling and marketing expense | - | 120,271 | - | - |
| General and administrative expense | - | 66,925 | - | - |
| Total selling, general and administrative expense | - | 187,196 | - | - |
| Other segment (expense) income | - | 8,763 | - | - |
| Net income from continuing operations | - | 49,341 | - | - |
| Net (loss) income | -66,480 | 49,341 | 82,761 | 109,562 |
| Depreciation and amortization | 19,429 | 3,846 | 8,080 | 15,239 |
| Amortization of inventory step-up | 12,726 | - | - | - |
| Share-based compensation expense | 36,330 | 26,275 | 24,665 | 47,776 |
| Deferred income taxes | -8,787 | -1,720 | 31,394 | -900 |
| Other non-cash charges | 1,294 | 915 | 1,151 | 3,245 |
| Contract liabilities | - | 0 | -578 | -671 |
| Receivables | 23,216 | -20,369 | -512 | -29,622 |
| Contract assets | - | -717 | -707 | -3,566 |
| Inventory | 6,427 | 4,863 | -845 | 10,043 |
| Prepaid expenses and other assets | 16,169 | -3,836 | 19,147 | -16,163 |
| Right-of-use assets | -2,165 | -1,921 | -1,915 | -3,713 |
| Accounts payable and accrued expenses | -119,472 | 73,029 | -28,245 | 56,109 |
| Accrued sales discounts, allowances and reserves | 748 | -5,617 | -430 | -19,279 |
| Operating lease liabilities | -2,773 | -2,587 | -2,596 | -5,137 |
| Other long-term liabilities | 4,889 | 4,607 | 638 | 48 |
| Proceeds from the sale of the athlone facility | - | 0 | 0 | 1,708 |
| Cash flows (used in) provided by operating activities | -165,743 | 170,069 | 101,672 | 249,013 |
| Additions of property, plant and equipment | 4,090 | -20 | 17,314 | 23,126 |
| Proceeds from the sale of property, plant and equipment | 9 | 1,052 | 0 | 34 |
| Business combination, net of cash acquired | 2,085,073 | - | - | - |
| Purchases of investments | 30,454 | 55,835 | 114,728 | 193,806 |
| Sales and maturities of investments | 42,608 | 377,109 | 125,305 | 195,078 |
| Cash flows (used in) provided by investing activities | -2,077,000 | 322,346 | -6,737 | -20,112 |
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements | 15,714 | 11,178 | 622 | 31,611 |
| Proceeds from the issuance of debt, net | 1,511,557 | - | - | - |
| Deferred financing costs paid to third-parties | 1,614 | - | - | - |
| Employee taxes paid related to net share settlement of equity awards | 23,442 | 266 | 307 | 30,459 |
| Payment for the repurchase of ordinary shares | 27,696 | - | - | - |
| Cash flows provided by financing activities | 1,474,519 | 10,912 | 315 | 1,152 |
| Net (decrease) increase in cash and cash equivalents | -768,225 | 503,327 | 95,250 | 230,053 |
| Cash, cash equivalents and restricted cash-beginning of period | 1,119,776 | -325,303 | 291,146 | - |
| Cash, cash equivalents and restricted cash-end of period | 351,551 | 503,327 | 616,449 | - |
Alkermes plc. (ALKS)
Alkermes plc. (ALKS)